Bio-Rad Laboratories Inc.

▲ Bull Case

• ◆Life Science organic growth re-accelerates to +7–10% by FY2026 as destocking ends sharply, pharma/biotech capex resumes, and ddPCR captures incremental gene therapy QC + liquid biopsy revenue worth $50–100M annually
• ◆Sartorius AG sustains recovery to €260+ on bioprocess normalization — Bio-Rad's stake worth $8B+ gross, $6.5B+ net, $200+ per share; market begins to price stake closer to NAV as recovery becomes durable
• ◆Operating margin reaches 18–19% by FY2029 via restructuring savings, mix shift to high-margin ddPCR consumables, and operating leverage on $3B+ revenue — Adj. EPS reaches ~$18 → 30x P/E = $540 operating-only + Sartorius credit drives total to ~$570

▼ Bear Case

• ◆NIH budget cut materializes at -15–20% in FY2026; academic Life Science demand stays depressed; Life Science organic growth remains negative through 2026
• ◆Sartorius AG re-traces to €120 as bioprocess recovery stalls; Bio-Rad's stake value drops $1.5B+ from current; another year of large GAAP losses drives retail selling and SOP discount widening
• ◆Operating leverage is muted because revenue recovery is slow; op. margin reaches only 12% by FY2029; ddPCR competitive pressure intensifies as patents expire — adj. EPS plateaus at $8–9 → 25–28x = $200–250 operating-only + impaired Sartorius credit drives total to $316

“The street is bifurcated on three core questions: (1) Is the destocking recovery real? Sequential improvement in Q2–Q3 2024 is encouraging, but the recovery has been 'next year' since 2023. Consensus FY2027 EPS at ~$9.30 implies modest confidence; Q1 2026 miss of $0.08 raises near-term doubts. (2) What is the right holdco discount on the Sartorius stake? Bulls argue 10–15%; bears argue 25–30%. The 5–10 point range is worth ~$60/share — a material valuation swing. (3) Can Bio-Rad close the margin gap vs. peers? Normalized op. margin of ~14–15% lags TMO (~21%), DHR (~26%), WAT (~27%), TECH (~37%). Bulls see operating leverage closing 200–300 bps; bears see structural subscale disadvantage.”

• ◆First quarter of positive Life Science organic growth (6–12 months) — Medium-High probability, +10–20% on confirmation
• ◆FY2027 guidance issued at Q4 2026 earnings (Feb 2027) — High event probability, ±10–15% impact
• ◆Restructuring savings ($60–100M) fully flowing through P&L — High probability, +200–400 bps op. margin uplift
• ◆Sartorius AG sustains recovery to €250+ on bioprocess normalization (1–3 years) — Medium probability, +$50–80/share
• ◆ddPCR adoption in MRD / liquid biopsy via FDA clearances (1–3 years) — Medium probability, +$10–30/share structural growth
• ◆Partial Sartorius stake monetization (~10% trim) funding buyback (1–3 years) — Low-Medium (25%) probability, +5–10% via narrower holdco discount
• ◆Operating margin reaches 15–17% at $3B+ revenue (3–5 years) — Medium probability, +$80–120/share via P/E expansion

• ◆NIH budget cut >20% materializes — Medium probability, $80–150M Life Science revenue headwind, structural demand impairment
• ◆Sartorius AG declines to €120 or below — Low-Medium probability, -$50–80/share via stake value erosion
• ◆Life Science destocking extends through FY2026 — Medium probability, $100–300M revenue gap vs. consensus
• ◆ddPCR patent expiry (2025–2030) triggers competitive pressure — Medium over 5–10yr horizon, 5–15% share loss to Thermo Fisher/Stilla
• ◆China geopolitical tension / domestic substitution accelerates — Medium probability, $100–200M impact over 3–5 years
• ◆Operating leverage disappoints on slow revenue recovery — Medium probability, 100–200 bps margin shortfall vs. plan
• ◆NGS displacement of PCR applications in research — Low-Medium (5–15yr horizon), 15–25% of Life Science TAM at risk